Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 3/10

vs
industry
vs
history
Cash-to-Debt 0.05
ECTE's Cash-to-Debt is ranked lower than
95% of the 799 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.09 vs. ECTE: 0.05 )
Ranked among companies with meaningful Cash-to-Debt only.
ECTE' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.02  Med: 116.7 Max: No Debt
Current: 0.05
Piotroski F-Score: 2
Altman Z-Score: -226.59
Beneish M-Score: -10.63
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
ROA % -549.06
ECTE's ROA % is ranked lower than
99% of the 799 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.49 vs. ECTE: -549.06 )
Ranked among companies with meaningful ROA % only.
ECTE' s ROA % Range Over the Past 10 Years
Min: -549.06  Med: -93.3 Max: -35.73
Current: -549.06
-549.06
-35.73
ROC (Joel Greenblatt) % -2383.91
ECTE's ROC (Joel Greenblatt) % is ranked lower than
93% of the 785 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 13.40 vs. ECTE: -2383.91 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
ECTE' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -7978.26  Med: -4312.95 Max: -967.71
Current: -2383.91
-7978.26
-967.71
3-Year Revenue Growth Rate -100.00
ECTE's 3-Year Revenue Growth Rate is ranked lower than
99% of the 607 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 5.70 vs. ECTE: -100.00 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
ECTE' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 0  Med: -87.9 Max: 44.2
Current: -100
0
44.2
3-Year EBITDA Growth Rate -13.30
ECTE's 3-Year EBITDA Growth Rate is ranked lower than
83% of the 583 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 9.40 vs. ECTE: -13.30 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
ECTE' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -53.4  Med: -23.8 Max: 14.6
Current: -13.3
-53.4
14.6
3-Year EPS without NRI Growth Rate -14.10
ECTE's 3-Year EPS without NRI Growth Rate is ranked lower than
76% of the 551 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.00 vs. ECTE: -14.10 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
ECTE' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -48.8  Med: -28.1 Max: 1602
Current: -14.1
-48.8
1602
GuruFocus has detected 3 Warning Signs with Echo Therapeutics Inc $ECTE.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» ECTE's 30-Y Financials

Financials (Next Earnings Date: 2017-08-12 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

ECTE Guru Trades in

ECTE Guru Trades in

Q2 2016

ECTE Guru Trades in Q2 2016

Jim Simons 17,400 sh (New)
» More
Q3 2016

ECTE Guru Trades in Q3 2016

Jim Simons Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with ECTE

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Major    NAICS: 325412    SIC: 2834
Compare:OTCPK:ENZB, OTCPK:ATHJF, NAS:BSPM, AMEX:CPHI, OTCPK:SUWN, OTCPK:INNV, NAS:NVGN, NAS:ALQA, NAS:IMNP, AMEX:AXN, NAS:TNXP, NAS:PRPH, OTCPK:PXSLY, NAS:OASM, AMEX:NNVC, NAS:ALIM, NAS:NBRV, NAS:ZGNX, NAS:RMTI, OTCPK:ABSCF » details
Traded in other countries:XS5B.Germany,
Headquarter Location:USA
Echo Therapeutics Inc is a medical device company with expertise in skin permeation technology. It develops non-invasive, wireless continuous glucose monitoring system with potential use in the wearable-health consumer & the diabetes outpatient market.

Echo Therapeutics Inc was incorporated in Delaware in September 2007 under the name Durham Pharmaceuticals Acquisition Co. It is a medical device company with expertise in skin permeation technology. The Companys medical device program is Symphony, a non-invasive, wireless, continuous glucose monitoring system designed to provide reliable, real-time glucose data conveniently, continuously and cost-effectively. The Symphony CGM System incorporates its SkinPrep device, transdermal glucose sensor, wireless transmitter and data display monitor. It is developing its Prelude SkinPrep System as a platform technology to allow for enhanced skin permeation that will enable two important applications; analyte extraction and needle-free drug delivery. It currently has two key strategic partnerships in place. It has granted Ferndale Pharma Group, Inc. a license to develop, market and sell the Prelude device for enhanced and needle-free delivery of topical anesthetics prior to needle insertion. It has also granted Handok Pharmaceuticals Co., Ltd. a license to develop, market and sell the Symphony CGM System for continuous glucose monitoring in South Korea. The Company competes with Edwards Lifesciences Corporation, Optiscan Biomedical Corp., Maquet Critical Care AB, Medtronic, Inc. A. Menarini Diagnostics S.r.l., Roche, Johnson & Johnson, Bayer and Abbott Laboratories. Government authorities in the United States, at the federal, state and local level, the European Union, and other countries extensively regulate the research, development, testing, manufacture, labeling, promotion, advertising, distribution, marketing, export and import of products such as those the Company are developing.

Ratios

vs
industry
vs
history
EV-to-EBIT -0.68
ECTE's EV-to-EBIT is ranked lower than
99.99% of the 776 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 20.99 vs. ECTE: -0.68 )
Ranked among companies with meaningful EV-to-EBIT only.
ECTE' s EV-to-EBIT Range Over the Past 10 Years
Min: -30.4  Med: -1.4 Max: 42.5
Current: -0.68
-30.4
42.5
EV-to-EBITDA -0.69
ECTE's EV-to-EBITDA is ranked lower than
99.99% of the 797 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 15.26 vs. ECTE: -0.69 )
Ranked among companies with meaningful EV-to-EBITDA only.
ECTE' s EV-to-EBITDA Range Over the Past 10 Years
Min: -31.2  Med: -1.4 Max: 36.2
Current: -0.69
-31.2
36.2
Current Ratio 0.06
ECTE's Current Ratio is ranked lower than
99% of the 700 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.55 vs. ECTE: 0.06 )
Ranked among companies with meaningful Current Ratio only.
ECTE' s Current Ratio Range Over the Past 10 Years
Min: 0.02  Med: 1.18 Max: 27.55
Current: 0.06
0.02
27.55
Quick Ratio 0.06
ECTE's Quick Ratio is ranked lower than
99% of the 699 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.85 vs. ECTE: 0.06 )
Ranked among companies with meaningful Quick Ratio only.
ECTE' s Quick Ratio Range Over the Past 10 Years
Min: 0.02  Med: 1.18 Max: 27.55
Current: 0.06
0.02
27.55

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -35.80
ECTE's 3-Year Average Share Buyback Ratio is ranked lower than
90% of the 442 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: -4.30 vs. ECTE: -35.80 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
ECTE' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -111  Med: -42.1 Max: 0
Current: -35.8
-111
0

Valuation & Return

vs
industry
vs
history
Earnings Yield (Greenblatt) % -147.06
ECTE's Earnings Yield (Greenblatt) % is ranked lower than
99% of the 1046 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.36 vs. ECTE: -147.06 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
ECTE' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -147.06  Med: 3.4 Max: 5.3
Current: -147.06
-147.06
5.3

More Statistics

EPS (TTM) $ -1.28
Beta1.43
Short Percentage of Float2.40%
52-Week Range $0.04 - 2.84
Shares Outstanding (Mil)12.00

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)